Eribulin (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Eribulin" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

20nih.gov

4^th place

8^th place

12doi.org

2^nd place

5^th place

3eisai.com

low place

1drugs.com

399^th place

169^th place

1europa.eu

68^th place

28^th place

1termania.net

low place

34^th place

1fda.gov

447^th place

409^th place

1breastcancernow.org

low place

1degruyter.com

1,425^th place

1,482^nd place

1worldcat.org

5^th place

10^th place

breastcancernow.org

»Eribulin (Halaven)«. Breast Cancer Now (v angleščini). 5. junij 2015. Pridobljeno 15. septembra 2022.

degruyter.com

Hirata Y, Uemura D (1. januar 1986). »Halichondrins - antitumor polyether macrolides from a marine sponge«. Pure and Applied Chemistry. 58 (5): 701–710. doi:10.1351/pac198658050701. ISSN 1365-3075.

doi.org

Hirata Y, Uemura D (1. januar 1986). »Halichondrins - antitumor polyether macrolides from a marine sponge«. Pure and Applied Chemistry. 58 (5): 701–710. doi:10.1351/pac198658050701. ISSN 1365-3075.
Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, in sod. (Julij 2005). »The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth«. Molecular Cancer Therapeutics. 4 (7): 1086–1095. doi:10.1158/1535-7163.MCT-04-0345. PMID 16020666.
Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (Julij 2008). »Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase«. Molecular Cancer Therapeutics. 7 (7): 2003–2011. doi:10.1158/1535-7163.MCT-08-0095. PMC 2562299. PMID 18645010.
Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA (Februar 2010). »Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability«. Biochemistry. 49 (6): 1331–7. doi:10.1021/bi901810u. PMC 2846717. PMID 20030375.
Wilson L, Lopus M, Miller HP, Azarenko O, Riffle S, Smith JA, Jordan MA (Oktober 2015). »Effects of eribulin on microtubule binding and dynamic instability are strengthened in the absence of the βIII tubulin isotype«. Biochemistry. 54 (42): 6482–9. doi:10.1021/acs.biochem.5b00745. PMID 26435331.
Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, in sod. (Avgust 2004). »Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389«. Cancer Research. 64 (16): 5760–5766. doi:10.1158/0008-5472.CAN-04-1169. PMID 15313917.
Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, in sod. (Januar 2011). »Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions«. Cancer Research. 71 (2): 496–505. doi:10.1158/0008-5472.CAN-10-1874. PMID 21127197.
Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, in sod. (Oktober 2014). »Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models«. Cancer Science. 105 (10): 1334–1342. doi:10.1111/cas.12488. PMC 4462349. PMID 25060424.
Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, in sod. (Marec 2014). »Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states«. British Journal of Cancer. 110 (6): 1497–505. doi:10.1038/bjc.2014.80. PMC 3960630. PMID 24569463.
Laughney AM, Kim E, Sprachman MM, Miller MA, Kohler RH, Yang KS, in sod. (november 2014). »Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin«. Science Translational Medicine. 6 (261): 261ra152. doi:10.1126/scitranslmed.3009318. PMC 4330962. PMID 25378644.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Seletsky BM, Wang Y, Hawkins LD, Palme MH, Habgood GJ, DiPietro LV, in sod. (november 2004). »Structurally simplified macrolactone analogues of halichondrin B«. Bioorganic & Medicinal Chemistry Letters. 14 (22): 5547–5550. doi:10.1016/j.bmcl.2004.08.068. PMID 15482921.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Kim DS, Dong CG, Kim JT, Guo H, Huang J, Tiseni PS, Kishi Y (november 2009). »New syntheses of E7389 C14-C35 and halichondrin C14-C38 building blocks: double-inversion approach«. Journal of the American Chemical Society. 131 (43): 15636–41. doi:10.1021/ja9058475. PMID 19807076.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

drugs.com

»Eribulin (Halaven) Use During Pregnancy«. Drugs.com. 22. oktober 2019. Pridobljeno 9. julija 2020.

eisai.com

»U.S. FDA Approves Eisai's Anticancer Agent Halaven For The Treatment Of Advanced Liposarcoma« (tiskovna objava). Eisai Co., Ltd. 29. januar 2016. Pridobljeno 15. februarja 2021.
»Eisai Announces Japan Launch Of Anticancer Agent Halaven« (tiskovna objava). Eisai Co., Ltd. 19. julij 2011. Pridobljeno 15. februarja 2021.
»Anticancer Agent Halaven Approved For Treatment Of Locally Advanced Or Metastatic Breast Cancer In China« (tiskovna objava). Eisai Co., Ltd. 17. julij 2019. Pridobljeno 15. februarja 2021.

europa.eu

ema.europa.eu

»Eribulin EPAR«. Evropska agencija za zdravila (EMA). Pridobljeno 9. julija 2020.

fda.gov

»FDA approves first drug to show survival benefit in liposarcoma«. U.S. Food and Drug Administration (FDA) (tiskovna objava). 28. januar 2016. Pridobljeno 9. julija 2020. Članek vsebuje besedilo iz tega vira, ki je v javni domeni.

nih.gov

pubmed.ncbi.nlm.nih.gov

Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, in sod. (Februar 2001). »In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B«. Cancer Research. 61 (3): 1013–21. PMID 11221827.
Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E (Avgust 1991). »Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data«. The Journal of Biological Chemistry. 266 (24): 15882–15889. PMID 1874739.
Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, in sod. (Julij 2005). »The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth«. Molecular Cancer Therapeutics. 4 (7): 1086–1095. doi:10.1158/1535-7163.MCT-04-0345. PMID 16020666.
Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (Julij 2008). »Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase«. Molecular Cancer Therapeutics. 7 (7): 2003–2011. doi:10.1158/1535-7163.MCT-08-0095. PMC 2562299. PMID 18645010.
Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA (Februar 2010). »Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability«. Biochemistry. 49 (6): 1331–7. doi:10.1021/bi901810u. PMC 2846717. PMID 20030375.
Wilson L, Lopus M, Miller HP, Azarenko O, Riffle S, Smith JA, Jordan MA (Oktober 2015). »Effects of eribulin on microtubule binding and dynamic instability are strengthened in the absence of the βIII tubulin isotype«. Biochemistry. 54 (42): 6482–9. doi:10.1021/acs.biochem.5b00745. PMID 26435331.
Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, in sod. (Avgust 2004). »Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389«. Cancer Research. 64 (16): 5760–5766. doi:10.1158/0008-5472.CAN-04-1169. PMID 15313917.
Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, in sod. (Januar 2011). »Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions«. Cancer Research. 71 (2): 496–505. doi:10.1158/0008-5472.CAN-10-1874. PMID 21127197.
Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, in sod. (Oktober 2014). »Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models«. Cancer Science. 105 (10): 1334–1342. doi:10.1111/cas.12488. PMC 4462349. PMID 25060424.
Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, in sod. (Marec 2014). »Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states«. British Journal of Cancer. 110 (6): 1497–505. doi:10.1038/bjc.2014.80. PMC 3960630. PMID 24569463.
Kawano S, Asano M, Adachi Y, Matsui J (april 2016). »Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma«. Anticancer Research. 36 (4): 1553–1561. PMID 27069131.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Laughney AM, Kim E, Sprachman MM, Miller MA, Kohler RH, Yang KS, in sod. (november 2014). »Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin«. Science Translational Medicine. 6 (261): 261ra152. doi:10.1126/scitranslmed.3009318. PMC 4330962. PMID 25378644.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Seletsky BM, Wang Y, Hawkins LD, Palme MH, Habgood GJ, DiPietro LV, in sod. (november 2004). »Structurally simplified macrolactone analogues of halichondrin B«. Bioorganic & Medicinal Chemistry Letters. 14 (22): 5547–5550. doi:10.1016/j.bmcl.2004.08.068. PMID 15482921.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)
Kim DS, Dong CG, Kim JT, Guo H, Huang J, Tiseni PS, Kishi Y (november 2009). »New syntheses of E7389 C14-C35 and halichondrin C14-C38 building blocks: double-inversion approach«. Journal of the American Chemical Society. 131 (43): 15636–41. doi:10.1021/ja9058475. PMID 19807076.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

ncbi.nlm.nih.gov

Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (Julij 2008). »Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase«. Molecular Cancer Therapeutics. 7 (7): 2003–2011. doi:10.1158/1535-7163.MCT-08-0095. PMC 2562299. PMID 18645010.
Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA (Februar 2010). »Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability«. Biochemistry. 49 (6): 1331–7. doi:10.1021/bi901810u. PMC 2846717. PMID 20030375.
Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, in sod. (Oktober 2014). »Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models«. Cancer Science. 105 (10): 1334–1342. doi:10.1111/cas.12488. PMC 4462349. PMID 25060424.
Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, in sod. (Marec 2014). »Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states«. British Journal of Cancer. 110 (6): 1497–505. doi:10.1038/bjc.2014.80. PMC 3960630. PMID 24569463.
Laughney AM, Kim E, Sprachman MM, Miller MA, Kohler RH, Yang KS, in sod. (november 2014). »Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin«. Science Translational Medicine. 6 (261): 261ra152. doi:10.1126/scitranslmed.3009318. PMC 4330962. PMID 25378644.{{navedi časopis}}: Vzdrževanje CS1: samodejni prevod datuma (povezava)

dailymed.nlm.nih.gov

»Halaven- eribulin mesylate injection«. DailyMed. 2. december 2017. Pridobljeno 9. julija 2020.

termania.net

https://www.termania.net/slovarji/slovenski-medicinski-slovar/8398197/eribulin?query=Eribulin&SearchIn=All, Slovenski medicinski e-slovar, vpogled: 29. 10. 2023.

worldcat.org

Hirata Y, Uemura D (1. januar 1986). »Halichondrins - antitumor polyether macrolides from a marine sponge«. Pure and Applied Chemistry. 58 (5): 701–710. doi:10.1351/pac198658050701. ISSN 1365-3075.